The most common treatment-related adverse events (TRAEs) were elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (16 of 44, 36.4%), followed by diarrhea (13 of 44, 29.5%), post-embolization syndrome (PES) (13 of 18, 72.2%), skin reactions (12 of 44, 27.3%), and hypertension (10 of 44, 22.7%) (Table 4). Here, GPT is linked to hypertensive disorder.